Eli Lilly’s Oral Obesity Drug Nears Key Milestone as Pipeline Expands

Eli Lilly has provided a more definitive timeline for one of its most anticipated pipeline assets. During a presentation at the TD Cowen Healthcare Conference on Monday, Chief Financial Officer Lucas Montarce confirmed that the company’s oral obesity treatment, orforglipron, could potentially launch in the United States as early as the second quarter of 2026. This launch is contingent upon receiving approval from the U.S. Food and Drug Administration (FDA). Despite this positive development, the company’s shares closed the session with a 3.2% decline.

Financial Performance and Valuation Context

The pharmaceutical giant’s current valuation continues to be a topic of market discussion. With a market capitalization approaching the $1 trillion threshold, Eli Lilly stands as the world’s most valuable healthcare company. Shareholders have been rewarded with gains exceeding 400% over the past five years. However, analysts frequently scrutinize its price-to-earnings ratio of 45 and a dividend yield of just 0.6%, debating the sustainability of its premium valuation.

This valuation is underpinned by explosive growth, predominantly driven by its GLP-1 franchise. In 2025, the company’s total revenue surged by 45%. For the current fiscal year 2026, management has issued a revenue guidance range of $80 to $83 billion. The fourth quarter of 2025 alone saw sales reach $19.3 billion.

Dominance of the GLP-1 Portfolio

The revenue growth is overwhelmingly attributed to two blockbuster injectable drugs: Mounjaro and Zepbound. Sales of Mounjaro increased by an impressive 99% in 2025, while Zepbound’s revenue skyrocketed by 175%. Together, these two medications accounted for nearly all of the firm’s sales growth last year, solidifying Eli Lilly’s commanding position in the metabolic disease market.

CFO Montarce acknowledged the persistent pricing pressures facing the pharmaceutical industry both domestically and globally. He emphasized that the company’s strategy to counter this trend revolves around continuous innovation and expanding patient access through volume growth.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Spotlight on Orforglipron’s Potential

The upcoming oral therapy, orforglipron, represents a significant strategic expansion. It aims to offer an alternative to injectable treatments, potentially capturing a segment of patients who are hesitant about injections. Regulatory applications for the drug have already been submitted in more than 40 countries worldwide.

Clinical data has been compelling. In the 52-week ACHIEVE-3 study, orforglipron demonstrated superior efficacy compared to oral semaglutid, achieving a greater reduction in HbA1c levels (2.2% versus 1.4%) and leading to more substantial weight loss (9.2% versus 5.3%).

Montarce outlined that, pending FDA clearance, the company is prepared to begin patient shipments within one week of approval. In a clear signal of confidence in global demand, Eli Lilly has already built an inventory of the drug valued at approximately $1.5 billion. The CFO cautioned, however, that this inventory figure should not be interpreted as a direct indicator of 2026 revenue.

Broader Pipeline and Strategic Moves

Beyond orforglipron, Eli Lilly is actively broadening its therapeutic portfolio. In a recent strategic acquisition, the company agreed to purchase Orna Therapeutics for up to $2.4 billion. Furthermore, the European Medicines Agency recently recommended Olumiant for treating adolescents with severe alopecia areata, with a U.S. decision on this indication anticipated in the second half of 2026.

The coming months are critical for the Indianapolis-based firm. The FDA’s decision on orforglipron in Q2 2026 will be a major test of its ability to extend its lead in the highly lucrative obesity drug market. A successful approval would add a convenient oral option to its already dominant GLP-1 franchise, potentially unlocking the next phase of growth.